IMS Solutions

We are delighted to announce the launch of IMS Solutions, supported by more than £3 million in funding to advance new diagnostic solutions for conditions featuring disordered steroid hormone metabolism.   There is a significant unmet need. These conditions can present with diffuse and diverse symptoms, making them difficult, time-consuming and costly to diagnose.   Our technology is designed to address this diagnostic challenge by detecting unique steroid signatures in urine and blood.   The funding will enable us to refine, advance and launch ACCelerate™, our urine test for the early diagnosis of Adrenocortical Carcinoma (ACC), as well as develop a new stratification test for Polyendocrine Metabolic Ovarian Syndrome (PMOS).   Led by Martin Whitaker, CEO, Wiebke Arlt, CSO and Liz Dainty, CFO, IMS Solutions brings together commercial, scientific and clinical expertise to bring this technology to market.   Read the full announcement on our website to find out more about the funding, the unmet need and our technology: https://lnkd.in/e4mJvFv4 #IMSSolutions #AdrenalCancer #ACC #CancerDiagnostics #MassSpectrometry #MachineLearning

We are delighted to announce the launch of IMS Solutions, supported by more than £3 million in funding to advance new diagnostic solutions for conditions featuring disordered steroid hormone metabolism.   There is a significant unmet need. These conditions can present with diffuse and diverse symptoms, making them difficult, time-consuming and costly to diagnose.   Our technology is designed to address this diagnostic challenge by detecting unique steroid signatures in urine and blood.   The funding will enable us to refine, advance and launch ACCelerate™, our urine test for the early diagnosis of Adrenocortical Carcinoma (ACC), as well as develop a new stratification test for Polyendocrine Metabolic Ovarian Syndrome (PMOS).   Led by Martin Whitaker, CEO, Wiebke Arlt, CSO and Liz Dainty, CFO, IMS Solutions brings together commercial, scientific and clinical expertise to bring this technology to market.   Read the full announcement on our website to find out more about the funding, the unmet need and our technology: https://lnkd.in/e4mJvFv4 #IMSSolutions #AdrenalCancer #ACC #CancerDiagnostics #MassSpectrometry #MachineLearning

From a simple urine sample to diagnostic insight. It starts with something remarkably simple: A urine sample taken at home. But what that sample can reveal is far more sophisticated. IMS Solutions is developing a non-invasive approach to adrenal cancer diagnosis based on steroid profiling in urine. Using mass spectrometry and machine learning, our technology analyses steroid signatures associated with Adrenocortical Carcinoma (ACC). The resulting diagnostic information can help distinguish malignant adrenal tumours from those that are benign. Supporting more timely and informed treatment decisions. A simple sample. Sophisticated science. Valuable diagnostic insight. #AdrenalCancer #ACC #CancerDiagnostics #MassSpectrometry #MachineLearning

What if a simple urine sample could help improve the diagnosis of adrenal cancer? That’s the possibility we’re working towards at Intelligent Mass Spec Solutions. Our technology analyses steroid signatures in urine to help identify Adrenocortical Carcinoma (ACC) and distinguish malignant adrenal tumours from those that are benign. No invasive procedure. Just sophisticated analysis of what a urine sample can reveal. By combining clinical expertise, high throughput mass spectrometry and machine learning, we’re developing a fast, accurate and non-invasive approach to adrenal tumour diagnosis. In our short video, we explain how it works — and introduce the science behind IMS Solutions. Watch the video: https://lnkd.in/eScgggrG Find out more about our work at https://lnkd.in/edCg-Yke #IMSSolutions #AdrenalCancer #ACC #MassSpectrometry #MachineLearning #CancerDiagnostics #MedTech

Meet the founding team behind Intelligent Mass Spec Solutions (IMS Solutions). IMS Solutions brings together scientific, clinical, commercial and financial expertise with a shared ambition: to improve the diagnosis of adrenal cancer. Wiebke Arlt — Chief Scientific Officer Martin Whitaker — Chief Executive Officer Liz Dainty — Chief Financial Officer Together, the team is working to translate pioneering research into a fast, accurate and non-invasive approach to adrenal tumour diagnosis, combining clinical expertise, high-quality mass spectrometry and machine learning. Our technology analyses steroid signatures in urine to help distinguish malignant adrenal tumours from those that are benign, supporting timely and informed clinical decision-making. Over the coming weeks, we will be sharing more about the team, the science behind our technology and the development of IMS Solutions. Follow IMS Solutions to learn more. Visit our website: https://lnkd.in/edCg-Yke #IMSSolutions #AdrenalCancer #CancerDiagnostics #MassSpectrometry #MachineLearning